Learn More
Description
RBN-2397 is a potent and selective PARP7 inhibitor (IC50< 3 nM, KD = 0.22 nM in a probe displacement assay; IC50 = 1 nM in a NanoBRET assay). It displays >500-fold selectivity over PARP12 and >50-fold selectivity over all other PARPs.RBN-2397 inhibits MARylation of multiple intracellular proteins in PARP7-overexpressing SK-MES-1 cells (IC50 = 2 nM), showing a 300-fold window over the inhibition of PARylation in PARP1-activated HeLa cells. It restores the Type I interferon (IFN) response in tumor cells and induces antitumor immunity dependent on Type I IFN and CD8 cells. Significantly increases the proportion of cells in the G0/G1 phase of the cell cycle. In xenograft models, it slows tumor growth (TGI: 49-67%), with complete tumor regression in the NCI-H1373 xenograft. RBN-2397 is orally bioavailable.
Specifications
Specifications
| Chemical Name or Material | 5-[[(1S)-1-Methyl-2-[3-oxo-3-[4-[5-(trifluoromethyl)-2-pyrimidinyl]-1-piperazinyl]propoxy]ethyl]amino]-4-(trifluoromethyl)-3(2H)-pyridazinone |
| CAS | 2381037-82-5 |
| Quantity | 50 mg |
| Product Line | Tocris |
| Target | Poly(ADP-ribose) Polymerase Inhibitors |
| Molecular Formula | C20H23F6N7O3 |
| Purity | 98% |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
